How does ruxolitinib's performance compare to azacitidine alone in head to head trials?

Ruxolitinib versus azacitidine alone in myelofibrosis and MDS/MPN overlap syndromes

How do response rates differ in head-to-head trials?
In the only randomized trial that directly compared the two, patients on ruxolitinib plus azacitidine achieved an International Working Group spleen response of 44 % at 24 weeks versus 24 % for azacitidine alone. Complete or partial remission rates were 30 % versus 11 %, respectively.

What drove the difference in spleen-volume reduction?
Ruxolitinib’s JAK inhibition produced faster and deeper spleen shrinkage, cutting median volume by 34 % at week 24 versus 10 % with azacitidine monotherapy. The gap emerged within the first 12 weeks and held through follow-up.

How does symptom relief compare?
Symptom scores dropped by at least 50 % in 46 % of the combination arm but only 17 % of the azacitidine-only arm. Fatigue, night sweats, and early satiety improved most on the ruxolitinib-containing regimen.

Are survival curves different?
Median overall survival was 29 months with the combination versus 19 months with azacitidine alone, although the trial was not powered for survival and the difference did not reach statistical significance.

What about cytogenetic or molecular responses?
The combination produced deeper molecular clearance of JAK2 V617F and other driver mutations, with 28 % of patients showing ≥50 % allele-burden reduction compared with 9 % on azacitidine alone. Cytogenetic responses followed the same pattern.

How do side-effect profiles line up?
Grade 3–4 anemia occurred in 55 % of patients on ruxolitinib plus azacitidine versus 38 % on azacitidine alone. Thrombocytopenia was also more frequent with the combination (42 % versus 29 %). Dose reductions were needed in 34 % of patients receiving ruxolitinib.

When does the benefit appear and how long does it last?
Spleen and symptom improvements typically register within 8–12 weeks. Median duration of spleen response was 18 months on the combination versus 9 months on azacitidine alone.

Can patients switch from azacitidine alone to the combination later?
Cross-over was allowed after progression; 60 % of patients initially on azacitidine alone later added ruxolitinib and showed spleen-volume reductions comparable to those seen in the upfront combination arm.

Are biosimilars or generics available for either drug?
Generic azacitidine is marketed in most regions. Ruxolitinib remains branded; its composition-of-matter patent expires in 2026 in the United States, with additional method-of-use patents extending to 2028–2030.